Arcus Biosciences, Inc. (RCUS) Stock Analysis
Breakout setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $24.41: Quality below floor (3.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10. Specifically: High short interest: 15%; Below-average business quality.
Arcus Biosciences is a late clinical-stage biopharmaceutical company developing small molecules for cancer (casdatifan for ccRCC in Phase 3, quemliclustat for pancreatic cancer, domvanalimab for NSCLC) and inflammation/autoimmune diseases. Revenue comes primarily from Gilead... Read more
Sell if holding. Engine safety override at $24.41: Quality below floor (3.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10. Specifically: High short interest: 15%; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 59, MACD bullish. Score 5.4/10, moderate confidence.
Passes 4/7 gates (clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and earnings proximity 5d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHCustomerGilead10-K Item 1A: 'We expect to depend on our collaboration with Gilead for the research, development, manufacture and commercialization of certain of our investigational products.'
Material Events(8-K, last 90d)
- 2026-03-23Item 5.02MEDIUMJennifer Jarrett (COO) resigned effective March 30, 2026. No disagreement cited. No successor named; she will provide advisory services through June 30, 2026.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers·1 ceiling hit
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $24.41: Quality below floor (3.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10. Specifically: High short interest: 15%; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 59, MACD bullish. Prior stop was $22.71. Score 5.4/10, moderate confidence.
Take-profit target: $29.58 (+21.2% upside). Prior stop was $22.71. Stop-loss: $22.71.
Concentration risk — Customer: Gilead; Quality below floor (3.0 < 4.0).
Arcus Biosciences, Inc. trades at a P/E of N/A (forward -6.8). TrendMatrix value score: 5.3/10. Verdict: Sell.
18 analysts cover RCUS with a consensus score of 4.1/5. Average price target: $34.
What does Arcus Biosciences, Inc. do?Arcus Biosciences is a late clinical-stage biopharmaceutical company developing small molecules for cancer (casdatifan...
Arcus Biosciences is a late clinical-stage biopharmaceutical company developing small molecules for cancer (casdatifan for ccRCC in Phase 3, quemliclustat for pancreatic cancer, domvanalimab for NSCLC) and inflammation/autoimmune diseases. Revenue comes primarily from Gilead Sciences collaboration payments; no product revenue to date.